Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes. Study participants were randomly ...

The PDUFA target date was set for March 26, 2025. The Food and Drug Administration has granted Priority Review to gepotidacin for the treatment of female adult and adolescent patients aged 12 years ...

Urinary tract infection (UTI) symptoms are, unfortunately, most often the ones that land in IYKYK territory, no matter how hard you try to brush them off. Whether you find yourself sitting on the ...